Search results
Results from the WOW.Com Content Network
Treatment of excessive daytime sleepiness (EDS) relies on identifying and treating the underlying disorder which may cure the person from the EDS. Drugs like modafinil , [ 22 ] armodafinil , [ 23 ] pitolisant [ 24 ] (Wakix), sodium oxybate (Xyrem) oral solution, have been approved as treatment for EDS symptoms in the United States.
No cure for Ehlers–Danlos syndrome is known, and treatment is supportive. Close monitoring of the cardiovascular system, physiotherapy, occupational therapy, and orthopedic instruments (e.g., wheelchairs, bracing, casting) may be helpful. This can help stabilize the joints and prevent injury.
The Ehlers–Danlos Society is an international nonprofit organization dedicated to patient support, scientific research, advocacy, and increasing awareness for the Ehlers–Danlos syndromes (EDS) and hypermobility spectrum disorder (HSD). [1] The society has organized multiple events around the world in an attempt to raise awareness for EDS ...
This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical treatment of sexual dysfunction but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in June 2017.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .
The first list was published in 1977 and included 208 medications. [8] [2] [9] The WHO updates the list every two years. [10] There are 306 medications in the 14th list in 2005, [11] 410 in the 19th list in 2015, [10] 433 in the 20th list in 2017, [12] [13] 460 in the 21st list in 2019, [14] [15] [16] and 479 in the 22nd list in 2021.
Dopamine agonists are mainly used in the treatment of Parkinson's disease. [2] The cause of Parkinson's is not fully known but genetic factors, for example specific genetic mutations, and environmental triggers have been linked to the disease. [4]
In combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in people aged two years of age and older [2] Asciminib: Novartis: Treatment of adults with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) [2] Blinatumomab